Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Reithera Srl is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This specific action represents the current state of the company's patent prosecution. The presence of 1 pending office action suggests a concentrated effort to secure intellectual property rights within this technical domain.
The prosecution is managed through 1 distinct art unit and involves 1 distinct examiner. This concentration indicates that the company's current applications are being evaluated within a specific technical niche. For a practitioner, the involvement of 1 distinct examiner means that the prosecution strategy is not diversified across various perspectives at the patent office.
SALVOZA, M FRANCO G is the busiest examiner for this portfolio, with a busiest examiner pending count of 1. This examiner is responsible for the 1 pending office action currently active. The success of the company's pending matters is therefore tied to the examination requirements of SALVOZA, M FRANCO G. Practitioners should monitor the tendencies of SALVOZA, M FRANCO G to anticipate the next steps in the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003858 | GORILLA ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF | SALVOZA, M FRANCO G | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003858 | GORILLA ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF | SALVOZA, M FRANCO G | 12d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003858 | GORILLA ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF | SALVOZA, M FRANCO G | 1672 | §101§112 | Final Rejection | 12d | Pending | Dec 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial